Double Hormone Syndromes in Two Pancreatic Neuroendocrine Tumours

Neuroendocrine tumours of the pancreas have an annual incidence of approximately per 100,000 population. Up to 85% ofthese tumours secrete peptides, many of which cause characteristic clinical syndromes. While pancreatic neuroendocrine tumours frequently express immunoreactivity for multiple peptides, they rarely produce more than one clinical syndrome due to excess peptide secretion. We report two patients with pancreatic neuroendocrine neoplasia in each of whom there were characteristic clinical features due to hypersecretion oftwo bioactive peptides.